Company Overview of Baliopharm AG
Baliopharm AG operates as a biotechnology company that focuses on the development of novel therapeutics for the treatment of immune mediated inflammatory diseases and cancer. The company was incorporated in 2007 and is headquartered in Basel, Switzerland with a subsidiary in Jülich, Germany. As of April 10, 2018, Baliopharm AG operates as a subsidiary of PROMETHERA Biosciences S.A./N.V.
Founded in 2007
41 61 2053 910
41 61 2053 919
Key Executives for Baliopharm AG
Similar Private Companies By Industry
|AB2 Bio Ltd.||Europe|
|ADC Products Switzerland SARL||Europe|
|ADC Therapeutics SA||Europe|
|AlloCyte Pharmaceuticals AG||Europe|
Recent Private Companies Transactions
April 10, 2018
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.
Most Searched Private Companies
|Company Name||Geographic Region|
|Lawyers Committee for Civil Rights Under Law||United States|
|The Advertising Council, Inc.||United States|
|Tax Management Inc||United States|
|John F. Kennedy Center For The Performing Arts||United States|
|NYC2012, Inc.||United States|
Sponsored Financial Commentaries
Only a company representative may request an update for the company profile. Documentation will be required.
To contact Baliopharm AG, please visit www.baliopharm.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.